ICCMIcecure Medical Ltd

IceCure Highlights Expanding Commercial Adoption of ProSense Cryoablation in Brazil Following FDA Clearance for Breast Cancer IceCure Highlights Expanding Commercial Adoption of ProSense Cryoablation in Brazil Following FDA Clearance for Breast Cancer PR Newswire CAESAREA, Israel, July 6, 2026...

IceCure Medical (NASDAQ: ICCM) has officially regained compliance with Nasdaq's minimum bid price requirement. Read the details.read more...

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire CAESAREA, Israel, June 25, 2026 CAESAREA, Israel, June 25, 2026 /PRNewswire/ --IceCure Medical Ltd.(NASDAQ: ICCM) ("IceCure", "IceCure Medical" or...

Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's regular session. The market value of their outstanding shares is at $22.1 million. Icecure Medical (NASDAQ:ICCM) stockread more...

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's...

The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand commercialization efforts. Recent developments from CervoMed (NASDAQ:CRVO), Butterfly Network (NYSE:BFLY), NeOnc (NASDAQ:NTHI), Spero Therapeutics (NASDAQ:SPRO), GSK (NYSE:GSK), and IceCure Medical (NASDAQ:ICCM) highlight several emerging themes shaping the sector, including neurodegenerative disease treatment, AI-powered diagnostics, antimicrobial resistance, minimally invasive cancer care, and synthetic biology.

Major U.S. stock indexes closed lower on Wednesday, with the Dow Jones Industrial Average slipping 0.98% to 51,942.55.read more...

IceCure Medical (NASDAQ:ICCM) captured investor attention after reporting, this morning, strong commercial momentum following FDA marketing authorization of its ProSense breast cancer cryoablation platform, as the company announced a 70% increase in its active U.S. commercial install base since receiving FDA clearance in October 2025.

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused...